The UK GLP-1 Reckoning: Private Budgets, High Hopes, and Fast Churn

GLP-1s have moved from clinical curiosity to mainstream conversation faster than almost any category in recent memory. And it's not just a medical story; it is a fundamental shift in consumer behaviour.

Our global tracking data reveals that the category is rapidly evolving from purely weight loss into holistic lifestyle management. People on these medications aren't just eating less, they are fundamentally changing how they shop, how they exercise, and how they view nutrition, with a massive shift toward viewing food as functional fuel rather than just enjoyment.

But the UK is not behaving like its European neighbours. It is a market defined by self-funding, private access routes, and most strikingly, a churn rate that should worry anyone banking on GLP-1s as a durable, long-term relationship.

Here's 5 key learnings from the data, as well as implications for brands:

1. The Affordability Paradox

The UK has a national health service and yet its GLP-1 users are the most self-funded in the market. 42% of UK Users pay entirely out of pocket, the highest of any of the five countries studied. Partial NHS reimbursement covers just 18% of users (behind France's 51% and Spain's 39%, and barely ahead of the fully-private US system).

For the Considering audience, cost is the single biggest thing standing between them and starting: 39% say they'd begin using GLP-1s immediately if fully reimbursed, and almost none of today's users (2%) say cost doesn't factor into their decision at all.

This isn't a nice-to-have consideration, it's the structural fact underpinning almost everything else in this report. It explains why the access route has gone private (see part 2), and it's the single largest lever for converting Considerers into Users.

2. The New Entry Point

Unsurprisingly, many early adopters of GLP-1s can trace their awareness back to a medical practitioner. 37% of UK Users were first made aware of the drugs via their GP, highlighting that initial uptake of the drugs was largely driven by those with a medical need. A striking 38% say their own online research was the biggest influence on their decision, the highest of any market by a wide margin.

However, the medical gatekeeper is beginning to disappear from the top of the UK funnel. Only 12% of UK Considerers first became aware of GLP-1s via their GP, the lowest of any market. Social media (24%), friends and family (22%) and TV advertising (17%) do the heavy lifting instead.

Consistent with this, UK Users are unusually reliant on pharmacist-direct prescribing (21%, the highest of any market) and Telehealth (expected by 16% of Considerers, also the highest).

The UK GLP-1 journey is evolving outside the traditional healthcare system - discovered on social media, researched independently online, and accessed through private pharmacy and Telehealth channels rather than a GP referral pathway.

3. The Stigma Gap

Here's a genuine paradox in the data. UK Considerers anticipate the least stigma of any market - only 10% expect to face judgement from others, the lowest of all five countries.

But UK Users report experiencing the most - 27% say they've actually felt stigmatised, the highest of any market. People underestimate the social cost before they start, then encounter more of it than their European peers once they're on treatment.

Side-effect anxiety follows a similar pre-adoption pattern: 54% of UK Considerers cite it as a top concern, tied for the highest of any market. But experience closes some of that gap fast - UK Users are twice as likely as UK Considerers to say prior concerns have since been resolved.

4. The Leaky Bucket

35% of everyone in the UK who has ever used a GLP-1 has now lapsed, second only to Spain, and well ahead of Germany, France, and the US. Crucially, access, not the medicine itself, is the primary driver.

Across all markets, the single largest satisfaction gap between Current and Lapsed Users is on ease of obtaining the medication (a 27-point gap), bigger than results, tolerability, or even value for money.

UK-specific evidence backs this up directly: supply issues at the pharmacy (23%) and prescription renewal problems (12%) are among the top reasons UK Users think about stopping, right alongside cost.

And once people lapse in the UK, the effect doesn't linger the way it does elsewhere. Every UK Lapsed User reports their eating habits eventually reverted to some degree, 0% say their habits "never returned," compared with meaningful minorities in France (12%), Spain (18%) and the US (9%) who maintain some lasting change.

9% of UK Lapsed Users say their habits have fully reverted - the highest full-reversion rate of any market.

5. Loyalty is Up For Grabs

Two-thirds of UK users are open to trying new brands to fit their changed needs, and the products winning their attention are protein-forward, low-sugar and explicitly labelled. "GLP-1 friendly" as a packaging claim resonates with 42% of UK Users, the highest of any market tested.

Retail experience is lagging demand: 39% of UK Users want a dedicated GLP-1-friendly aisle or online filter, and trust concentrates heavily on doctors and dieticians (39%) rather than influencers (6%), even though influencers are how many first heard about the category.

A format shift could accelerate all of this further: 81–83% of both UK Considerers and Users say they'd be more likely to use GLP-1s if a pill/tablet format became available - one of the few findings where every audience segment moves in lockstep.

Three things matter most for FMCG brands watching this category.

First, this is a value shopper, not a premium one - cost is already stretched by the medication itself, so affordability, own-label ranges and smart pack sizing will win more of this basket than premiumising the "GLP-1 friendly" claim.

Second, the GP has largely left this journey. From discovery through to daily use, this shopper is self-directing via social media, online research and pharmacy channels rather than a clinician, and navigating things like stigma largely alone. Brands have a real opening to fill the gap it leaves behind - as the trusted, practical, non-judgemental voice on how to actually eat and shop through it, visible wherever this shopper is looking, whatever stage they're at.

Third, don't build for a shopper who's permanently changed. A third of UK Users have already stopped, and their habits revert fast when they do. The brands that win here won't just capture this shopper while they're on treatment; they'll be the ones that help sustain the results, independent of the drug afterwards, and are ready to welcome them back if they restart.

Survey Background

We surveyed 1,721 consumers across 5 major markets (US, UK, France, Germany, and Spain). This article focuses on a robust sample of 333 UK respondents. Because we specifically targeted people engaged with the medication, this data represents the behaviours of the GLP-1 ecosystem, not national prevalence.

To map the complete lifecycle of a GLP-1 consumer, we deliberately split our UK audience into three highly specific segments

• Current Users (40%) - Those currently taking a GLP-1 medication. They show us how daily habits, grocery spending, and brand loyalty are changing right now.

• Lapsed Users (25%) - Those who used a GLP-1 in the past but have stopped. They are critical for understanding which new habits stick permanently, and which ones disappear the moment the medication stops.

• Considerers (35%) - Those seriously considering starting in the next 6 months. They reveal the future demand triggers, the barriers to entry, and what innovation (like pill formats) could unleash the next wave of users.

It is vital to understand that our UK audience spans a broad spectrum of health needs. GLP-1 usage is not one-size-fits-all. Our respondents range from those managing clinically diagnosed conditions - such as Type 2 diabetes, clinical obesity (BMI 30+), and cardiovascular disease - to those utilising the medication for elective weight management.